Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
Narjes Nasiri‐Ansari, Georgios K. Dimitriadis, Georgios Agrogiannis, et al.
Cardiovascular Diabetology (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies
Suowen Xu, Iqra Ilyas, Peter J. Little, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 3, pp. 924-967
Open Access | Times Cited: 662
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
Narjes Nasiri‐Ansari, Chrysa Nikolopoulou, Katerina Papoutsi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 818-818
Open Access | Times Cited: 218
Endothelial Protection by Sodium-Glucose Cotransporter 2 Inhibitors: A Literature Review of In Vitro and In Vivo Studies
N Mylonas, Panagiota Nikolaou, Paschalis Karakasis, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7274-7274
Open Access | Times Cited: 17
Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?
Paschalis Karakasis, Nikolaos Fragakis, Κωνσταντίνος Κούσκουρας, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 11, pp. 841-850
Closed Access | Times Cited: 16
Class effects of SGLT2 inhibitors on cardiorenal outcomes
Aaron Y. Kluger, Kristen M. Tecson, Andy Lee, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 135
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, et al.
Theranostics (2021) Vol. 11, Iss. 9, pp. 4502-4515
Open Access | Times Cited: 98
Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice
Byambasuren Ganbaatar, Daiju Fukuda, Masakazu Shinohara, et al.
European Journal of Pharmacology (2020) Vol. 875, pp. 173040-173040
Closed Access | Times Cited: 96
Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways
Raquibul Hasan, Shoumen Lasker, Ahasanul Hasan, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 88
SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models
Ioanna Andreadou, Robert M. Bell, Hans Erik Bøtker, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2020) Vol. 1866, Iss. 7, pp. 165770-165770
Open Access | Times Cited: 73
Immunomodulation and immunopharmacology in heart failure
George Markousis‐Mavrogenis, Lukas Baumhove, Ali A. Al‐Mubarak, et al.
Nature Reviews Cardiology (2023) Vol. 21, Iss. 2, pp. 119-149
Closed Access | Times Cited: 22
The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation
H. Salman, Adeeb A. Al-Zubaidy, Alaa Hamza Abbas, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 11
Sodium-glucose cotransporter 2 inhibitors attenuate vascular calcification by suppressing endoplasmic reticulum protein thioredoxin domain containing 5 dependent osteogenic reprogramming
Shaofa Wu, Xiaolin Luo, Chen Yang, et al.
Redox Biology (2024) Vol. 73, pp. 103183-103183
Open Access | Times Cited: 10
The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review
Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5408-5408
Open Access | Times Cited: 9
Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review
Habib Yaribeygi, Thozhukat Sathyapalan, Mina Maleki, et al.
Life Sciences (2019) Vol. 240, pp. 117090-117090
Open Access | Times Cited: 69
Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies
Afnan Alshnbari, Sophie Millar, Saoirse E. O’Sullivan, et al.
Diabetes Therapy (2020) Vol. 11, Iss. 9, pp. 1947-1963
Open Access | Times Cited: 69
Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1
Ghazaleh Behnammanesh, Giovanna L. Durante, Yash P. Khanna, et al.
Redox Biology (2020) Vol. 32, pp. 101527-101527
Open Access | Times Cited: 63
The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
Salvatore Carbone, Dave L. Dixon
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 61
Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice
Arief Rahadian, Daiju Fukuda, Hotimah Masdan Salim, et al.
Journal of Atherosclerosis and Thrombosis (2020) Vol. 27, Iss. 11, pp. 1141-1151
Open Access | Times Cited: 54
Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
Valentina Spigoni, Federica Fantuzzi, Cecilia Carubbi, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 52
Medium-, long- and medium-chain-type structured lipids ameliorate high-fat diet-induced atherosclerosis by regulating inflammation, adipogenesis, and gut microbiota in ApoE−/− mice
Chonghui Yue, Ming Li, Jing Li, et al.
Food & Function (2020) Vol. 11, Iss. 6, pp. 5142-5155
Closed Access | Times Cited: 51
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors
Azizah Ugusman, Jaya Kumar, Amilia Aminuddin
Pharmacology & Therapeutics (2021) Vol. 224, pp. 107832-107832
Closed Access | Times Cited: 47
Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
Yihai Liu, Jiamin Xu, Mingyue Wu, et al.
Lipids in Health and Disease (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 42
The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches
Panagiotis Tsioufis, Panagiotis Theofilis, Konstantinos Tsioufis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15937-15937
Open Access | Times Cited: 36
Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
Sandra Feijóo‐Bandín, Alana Aragón‐Herrera, Manuel Otero-Santiago, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5634-5634
Open Access | Times Cited: 34
Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease
Francesco Bellanti, Aurelio Lo Buglio, Michał Dobrakowski, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 26, pp. 3243-3257
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top